ATE373725T1 - Methoden zur feststellung von akute myeloischen leukämie - Google Patents
Methoden zur feststellung von akute myeloischen leukämieInfo
- Publication number
- ATE373725T1 ATE373725T1 AT02791197T AT02791197T ATE373725T1 AT E373725 T1 ATE373725 T1 AT E373725T1 AT 02791197 T AT02791197 T AT 02791197T AT 02791197 T AT02791197 T AT 02791197T AT E373725 T1 ATE373725 T1 AT E373725T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- patient
- detecting acute
- myeloic leukemia
- acute myeloic
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000032839 leukemia Diseases 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 abstract 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34093801P | 2001-10-30 | 2001-10-30 | |
| US34101201P | 2001-10-30 | 2001-10-30 | |
| US33899701P | 2001-10-30 | 2001-10-30 | |
| US34008101P | 2001-10-30 | 2001-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE373725T1 true ATE373725T1 (de) | 2007-10-15 |
Family
ID=27502594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02791197T ATE373725T1 (de) | 2001-10-30 | 2002-10-30 | Methoden zur feststellung von akute myeloischen leukämie |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20040110792A1 (de) |
| EP (1) | EP1478773B1 (de) |
| JP (1) | JP2005522990A (de) |
| KR (1) | KR20040065524A (de) |
| AT (1) | ATE373725T1 (de) |
| BR (1) | BR0206251A (de) |
| CA (1) | CA2451168A1 (de) |
| DE (1) | DE60222590T2 (de) |
| MX (1) | MXPA04004072A (de) |
| WO (1) | WO2003038129A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| EP1361433A3 (de) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Verfahren zur erkennung die therapeutisches Wirkung TNF |
| AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| WO2004058171A2 (en) | 2002-12-20 | 2004-07-15 | Protein Design Labs, Inc. | Antibodies against gpr64 and uses thereof |
| US20050283854A1 (en) | 2003-05-23 | 2005-12-22 | Anton Krumm | Recombinant vectors for use in position-independent transgene expression within chromatin |
| EP1502962A3 (de) * | 2003-07-01 | 2006-01-11 | Veridex, LLC | Methoden zur Einschätzung und zur Behandlung von Krebserkrankungen |
| US20050003422A1 (en) * | 2003-07-01 | 2005-01-06 | Mitch Reponi | Methods for assessing and treating cancer |
| CA2608359A1 (en) * | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
| WO2007021807A1 (en) * | 2005-08-12 | 2007-02-22 | Schering Corporation | Mcp1 fusions |
| ITRM20050475A1 (it) * | 2005-09-19 | 2007-03-20 | Univ Degli Studi Genova | Sequenze trascritte da rna polimerasi iii tipo iii e loro uso. |
| US20080199873A1 (en) * | 2006-12-04 | 2008-08-21 | Anderson Mark G | Companion diagnostic assays for cancer therapy |
| CN102317772A (zh) * | 2007-03-12 | 2012-01-11 | 维里德克斯有限责任公司 | 测定急性髓性白血病对用法尼基转移酶治疗的反应的方法 |
| WO2008156613A1 (en) * | 2007-06-12 | 2008-12-24 | Schering Corporation | Histone h2ax (hh2ax) biomarker for fti sensitivity |
| US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| WO2010062857A1 (en) | 2008-11-26 | 2010-06-03 | Allergan, Inc. | Klk-13 antibody inhibitor for treating dry eye |
| US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
| ES2705719T3 (es) | 2010-07-28 | 2019-03-26 | Janssen Diagnostics Llc | Métodos de determinación de la respuesta de la leucemia mieloide aguda al tratamiento con inhibidores de la farnesiltransferasa |
| US11559540B2 (en) | 2010-07-28 | 2023-01-24 | Janssen Pharmaceutica Nv | Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
| SMT202100712T1 (it) | 2015-08-17 | 2022-01-10 | Kura Oncology Inc | Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi |
| TW201818965A (zh) | 2016-11-03 | 2018-06-01 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303301B1 (en) * | 1997-01-13 | 2001-10-16 | Affymetrix, Inc. | Expression monitoring for gene function identification |
| US5968784A (en) * | 1997-01-15 | 1999-10-19 | Chugai Pharmaceutical Co., Ltd. | Method for analyzing quantitative expression of genes |
| US6203987B1 (en) * | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
| WO2001055170A1 (en) * | 2000-01-26 | 2001-08-02 | Vanderbilt University | Mob-5/hmob-5 as a cancer diagnostic marker |
| WO2001088850A2 (en) * | 2000-05-17 | 2001-11-22 | University Of South Florida | Statistical image analysis |
-
2002
- 2002-10-30 KR KR10-2003-7009841A patent/KR20040065524A/ko not_active Withdrawn
- 2002-10-30 JP JP2003540393A patent/JP2005522990A/ja active Pending
- 2002-10-30 US US10/283,975 patent/US20040110792A1/en not_active Abandoned
- 2002-10-30 AT AT02791197T patent/ATE373725T1/de not_active IP Right Cessation
- 2002-10-30 MX MXPA04004072A patent/MXPA04004072A/es not_active Application Discontinuation
- 2002-10-30 EP EP20020791197 patent/EP1478773B1/de not_active Expired - Lifetime
- 2002-10-30 BR BR0206251A patent/BR0206251A/pt not_active IP Right Cessation
- 2002-10-30 WO PCT/US2002/034784 patent/WO2003038129A2/en not_active Ceased
- 2002-10-30 CA CA 2451168 patent/CA2451168A1/en not_active Abandoned
- 2002-10-30 DE DE2002622590 patent/DE60222590T2/de not_active Expired - Fee Related
-
2006
- 2006-10-30 US US11/589,660 patent/US20070048782A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005522990A (ja) | 2005-08-04 |
| CA2451168A1 (en) | 2003-05-08 |
| EP1478773A2 (de) | 2004-11-24 |
| KR20040065524A (ko) | 2004-07-22 |
| DE60222590T2 (de) | 2008-06-19 |
| DE60222590D1 (de) | 2007-10-31 |
| MXPA04004072A (es) | 2004-09-06 |
| BR0206251A (pt) | 2004-06-15 |
| WO2003038129A2 (en) | 2003-05-08 |
| US20040110792A1 (en) | 2004-06-10 |
| EP1478773B1 (de) | 2007-09-19 |
| WO2003038129A3 (en) | 2004-09-10 |
| US20070048782A1 (en) | 2007-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE373725T1 (de) | Methoden zur feststellung von akute myeloischen leukämie | |
| WO2004053066A3 (en) | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy | |
| ATE403750T1 (de) | Methoden und kompositionen zur bewertung von antikörper behandlungen | |
| DE60228592D1 (de) | Verfahren zur erkennung von medikamentenempfindlichkeit in patienten mit entzündungskrankheiten | |
| HUP0302332A2 (hu) | Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére | |
| WO2004000094A3 (en) | Predictive markers in cancer therapy | |
| NO20052955L (no) | Behandling av Huntingtons sykdom med EPA | |
| DE602005021086D1 (de) | Pulsoximeter und verfahren zur vermittlung von sauerstoffsättigung und herzfrequenz | |
| NO20062646L (no) | System og fremgangsmate for a analysere medisinsk behandlingsdata | |
| NO20055832L (no) | Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme | |
| DE602006015442D1 (de) | Gerät zum nachweis von arrhythmie in einem medizinprodukt | |
| WO2005027993A3 (en) | Vascular access preservation in hemodialysis patients | |
| DK2332582T3 (da) | ACE2-aktivering til behandling af hjerte-, lunge-og nyresygdomme samt forhøjet blodtryk | |
| ATE461707T1 (de) | Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug | |
| AU2003293141A8 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| EP1612281A3 (de) | Verfahren zur Beurteilung von Patienten mit akuter myeloischer Leukämie | |
| DK1397681T3 (da) | Fremgangsmåde til identificering af midler til behandling af diabetes | |
| DK1144000T3 (da) | Ny fremgangsmåde til dialyse | |
| ATE529743T1 (de) | Verfahren und kits zur tumorigenizitätsdiagnose | |
| BRPI0502433A (pt) | métodos para avaliação e tratamento de cáncer | |
| WO2003087315A3 (en) | Pre-and post therapy gene expression profiling to identify drug targets | |
| EP1502962A3 (de) | Methoden zur Einschätzung und zur Behandlung von Krebserkrankungen | |
| CY1107921T1 (el) | Μεθοδος για την προγνωση της αθροιστικης επιβιωσης ασθενων | |
| EP1767656A3 (de) | Methoden zur feststellung und behandlung von leukämie | |
| DK1696790T3 (da) | Fremgangsmåder til vurdering af stofskiftesubstratudnyttelse og virkning af en terapi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |